Long‐Term Deep Brain Stimulation in Treatment‐Resistant Obsessive‐Compulsive Disorder: Outcome and Quality of Life at Four to Eight Years Follow‐Up. Issue 2 (15th July 2020)

• Record Type: Journal Article
• Authors: Winter, Lotta; Saryyeva, Assel; Schwabe, Kerstin; Heissler, Hans E.; Runge, Joachim; Alam, Mesbah; Heitland, Ivo; Kahl, Kai G.; Krauss, Joachim K.
• Is Part Of: Neuromodulaton. Volume 24:Issue 2(2021)
• Page Start: 324
• Page End: 330
• Publication Date: 2020-07-15
• Subjects: Case series -- deep brain stimulation for obsessive‐compulsive disorder -- long‐term electrical stimulation of bed nucleus of stria termi -- obsessive compulsive disorder -- stimulation; Central nervous system -- Physiology -- Periodicals; Central nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ner.13232
• Languages: English
• ISSNs: 1094-7159

Abstract

Abstract: Background: Obsessive compulsive disorder (OCD) is a severe disabling disease, and around 10% of patients are considered to be treatment‐resistant (tr) in spite of guideline‐based therapy. Deep brain stimulation (DBS) has been proposed as a promising treatment for patients with trOCD. However, the optimal site for stimulation is still a matter of debate, and clinical long‐term follow‐up observations including data on quality of life are sparse. We here present six trOCD patients who underwent DBS with electrodes placed in the bed nucleus of the stria terminalis/anterior limb of the internal capsule (BNST/ALIC), followed for four to eight years after lead implantation. Materials and Methods: In this prospective observational study, six patients (four men, two women) aged 32–51 years and suffering from severe to extreme trOCD underwent DBS of the BNST/ALIC. Symptom severity was assessed using the Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS), and quality of life using the World Health Organization Quality of Life assessment scale (WHO‐QoL BREF). Follow‐up was obtained at least for four years in all patients. Results: With chronic DBS for four to eight years, four of the six patients had sustained improvement. Two patients remitted and two patients responded (defined as >35% symptom reduction), while the other two patients were considered nonresponders on long‐term. Quality of life markedly improved in remitters and responders. We did not observe peri‐interventional side effects or adverse effects of chronic stimulation. Conclusions: Chronic DBS of ALIC provides long‐term benefit up to four to eight years in trOCD, although not all patients take profit. Targeting the BNST was not particularly relevant since no patient appeared to benefit from direct stimulation of the BNST. Quality of life improved in DBS responders, documented by improved QoL scores and, even more important, by regaining of autonomy and improving psychosocial functioning.